We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Ixico Plc | LSE:IXI | London | Ordinary Share | GB00BFXR4C20 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.25 | -3.28% | 7.375 | 7.25 | 7.50 | 7.625 | 7.375 | 7.625 | 65,696 | 11:23:58 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From May 2019 to May 2024
TIDMIXI
RNS Number : 6638S
IXICO plc
23 December 2016
23 December 2016
IXICO plc
("IXICO" or the "Company")
Buyback and cancellation of Deferred Shares
IXICO, the brain health company, announces that it has today repurchased, for nominal value, and cancelled deferred shares of 49 pence each in the share capital of the Company. The deferred shares
were issued as part of a share capital restructuring undertaken in conjunction with the acquisition of Optimal Medicine Group and as announced on 18 November 2015.
For further information please contact:
IXICO plc Derek Hill, Chief Executive Officer Tel: +44 20 3763 Susan Lowther, Chief Financial Officer 7499 Shore Capital (Nomad and Broker) Tel: +44 20 7408 Bidhi Bhoma / Edward Mansfield 4090 FTI Consulting Limited (Investor Tel: +44 20 3727 Relations) 1000 Simon Conway/Mo Noonan/Matthew Moss
About IXICO
IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions. In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes. In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.
The Company's brain health focus includes Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, behavioural health, child and adolescent mental health.
More information is available on www.ixico.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCAKBDKOBDDBBB
(END) Dow Jones Newswires
December 23, 2016 02:00 ET (07:00 GMT)
1 Year Ixico Chart |
1 Month Ixico Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
